Refractory ventricular fibrillation treated with esmolol.

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Refractory ventricular fibrillation (RVF) in out-of-hospital cardiac arrest (OHCA) presents a significant clinical challenge.
• Limited treatment options exist for patients with persistent RVF despite advanced cardiac life support measures.

Purpose of the Study:

• To evaluate the efficacy of esmolol in patients experiencing RVF during OHCA.
• To assess the impact of esmolol on return of spontaneous circulation (ROSC) and survival outcomes.

Main Methods:

• A single-center retrospective pre-post study design was employed.
• Patients with RVF (≥3 defibrillation attempts) received esmolol (loading dose: 500μg/kg, infusion: 0-100μg/kg/min) or served as controls.
• Data were collected from January 2012 to December 2015.

Main Results:

• Sustained ROSC was significantly higher in the esmolol group (56%) compared to the control group (16%) (p=0.007).
• Survival and good neurological outcomes at 30 days, 3 months, and 6 months were more than doubled in the esmolol group, though not statistically significant.
• The study included 16 patients in the esmolol group and 25 in the control group.

Conclusions:

• Esmolol administration may improve sustained ROSC rates in OHCA patients with RVF.
• Findings suggest a potential increase in ICU survival with esmolol for RVF in OHCA.
• Larger prospective studies are warranted to confirm the therapeutic effect of esmolol in this patient population.